{"disease":{"id":"relapsed-and-refractory-multiple-myeloma","name":"relapsed and refractory multiple myeloma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07222761","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":915,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03433001","title":"A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone","phase":"","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06153251","title":"A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":187,"lead_sponsor_name":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","has_results":false},{"nct_id":"NCT03029234","title":"Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03170882","title":"A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02223598","title":"A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"Cleave Biosciences, Inc.","has_results":false},{"nct_id":"NCT03715478","title":"Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Canadian Myeloma Research Group","has_results":false},{"nct_id":"NCT03477643","title":"Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)","phase":"","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT03140943","title":"Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false},{"nct_id":"NCT06182696","title":"OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":83,"lead_sponsor_name":"OriCell Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT05719701","title":"Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT05673967","title":"Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT00932698","title":"Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06103838","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03242460","title":"The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Kosin University Gospel Hospital","has_results":false},{"nct_id":"NCT06876142","title":"Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03416374","title":"A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02917941","title":"A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05530421","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04776018","title":"A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03683277","title":"IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"Intergroupe Francophone du Myelome","has_results":false},{"nct_id":"NCT05066022","title":"A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03836053","title":"Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02144038","title":"Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05486975","title":"This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03661554","title":"BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"The Pregene (ShenZhen) Biotechnology Company, Ltd.","has_results":false},{"nct_id":"NCT04017130","title":"A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Molecular Templates, Inc.","has_results":false},{"nct_id":"NCT04272775","title":"A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05893693","title":"Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Aibin Liang，MD，Ph.D.","has_results":false},{"nct_id":"NCT07234721","title":"SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03710915","title":"A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"HitGen Inc.","has_results":false},{"nct_id":"NCT06351644","title":"ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Adriana Rossi","has_results":false},{"nct_id":"NCT06479954","title":"Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04392648","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D LLC","has_results":false},{"nct_id":"NCT04534322","title":"Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Oncopeptides AB","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}